Key facts
- It has raised $1.8M; the latest was Seed Round ($1.0M) in Nov 2025.
- Notable investors include Creative Destruction Lab, Life Sciences BC, CELS Valley Ready, Hextwo Capital, New Ventures BC — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for CereCura Nanotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for CereCura Nanotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CereCura Nanotherapeutics
Operator of next-generation neurological therapeutics intended to treat brain disease. The company's platform combines lipid nanoparticle (LNP) delivery with RNA technology, enabling targeted, modular, and flexible delivery of nucleic-acid payloads to the central nervous system, overcoming the blood-brain barrier and supporting sustained protein production in the brain, enabling the biotech and pharmaceutical market to address unmet needs in neurological disorders.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2022
- Employees
- 9
- Website
- cerecura.com/
- Ownership
- Privately Held (backing)
CereCura Nanotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CereCura Nanotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CereCura Nanotherapeutics in its N-PORT filings yet. We sweep new filings monthly.